Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported E.P.S. of $-1.47 for its second fiscal quarter (ending March 31) versus $-1.79 for the same period a year ago. This result exceeded the consensus estimate of $-1.70 by $0.23. For the latest four quarters through March 31, E.P.S. were $-6.25 compared to $-5.99 a year ago.
Recent Price Action
On 5/6/24, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) stock declined by -3.8%, closing at $14.60. However, this decline was accompanied by unusually low trading volume at 57% of normal. Relative to the market the stock has been strong over the last nine months and has risen 18.0% during the last week.
Current PriceTarget Research Rating
ENTA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Enanta Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Enanta Pharmaceuticals has a very low Appreciation Score of 13 but a slightly positive Power Rating of 70, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment